Logo image of SURG

SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG - US86882L2043 - Common Stock

2.74 USD
+0.03 (+1.11%)
Last: 9/5/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SURG. SURG was compared to 21 industry peers in the Wireless Telecommunication Services industry. SURG may be in some trouble as it scores bad on both profitability and health. SURG has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURG has reported negative net income.
In the past year SURG has reported a negative cash flow from operations.
SURG had negative earnings in 4 of the past 5 years.
In multiple years SURG reported negative operating cash flow during the last 5 years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

SURG's Return On Assets of -320.77% is on the low side compared to the rest of the industry. SURG is outperformed by 95.24% of its industry peers.
With a Return On Equity value of -42037.73%, SURG is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -320.77%
ROE -42037.73%
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

SURG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

0

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SURG has been increased compared to 1 year ago.
Compared to 5 years ago, SURG has more shares outstanding
SURG has a worse debt/assets ratio than last year.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -12.46, we must say that SURG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.46, SURG is not doing good in the industry: 95.24% of the companies in the same industry are doing better.
SURG has a Debt/Equity ratio of 53.87. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SURG (53.87) is worse than 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 53.87
Debt/FCF N/A
Altman-Z -12.46
ROIC/WACCN/A
WACC8.7%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.11 indicates that SURG should not have too much problems paying its short term obligations.
SURG has a worse Current ratio (1.11) than 61.90% of its industry peers.
SURG has a Quick Ratio of 1.11. This is a bad value and indicates that SURG is not financially healthy enough and could expect problems in meeting its short term obligations.
SURG's Quick ratio of 0.84 is on the low side compared to the rest of the industry. SURG is outperformed by 80.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.84
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

SURG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2855.56%.
Looking at the last year, SURG shows a very negative growth in Revenue. The Revenue has decreased by -67.73% in the last year.
The Revenue has been growing by 18.83% on average over the past years. This is quite good.
EPS 1Y (TTM)-2855.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.97%
Revenue 1Y (TTM)-67.73%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-23.65%

3.2 Future

SURG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.97% yearly.
The Revenue is expected to grow by 83.41% on average over the next years. This is a very strong growth
EPS Next Y63.82%
EPS Next 2Y45.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year47.45%
Revenue Next 2Y83.41%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SURG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.95, the valuation of SURG can be described as reasonable.
Based on the Price/Forward Earnings ratio, SURG is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
SURG is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.95
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SURG's earnings are expected to grow with 45.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.97%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SURG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (9/5/2025, 8:00:01 PM)

2.74

+0.03 (+1.11%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners9.29%
Inst Owner Change-16.24%
Ins Owners30.9%
Ins Owner Change1.25%
Market Cap55.98M
Analysts80
Price Target9.18 (235.04%)
Short Float %2.02%
Short Ratio2.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-68.1%
Min EPS beat(2)-75.97%
Max EPS beat(2)-60.24%
EPS beat(4)0
Avg EPS beat(4)-152.16%
Min EPS beat(4)-304.04%
Max EPS beat(4)-60.24%
EPS beat(8)1
Avg EPS beat(8)-184.11%
EPS beat(12)4
Avg EPS beat(12)-2.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.44%
Min Revenue beat(2)-30.02%
Max Revenue beat(2)-14.86%
Revenue beat(4)1
Avg Revenue beat(4)-19.09%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)14.43%
Revenue beat(8)2
Avg Revenue beat(8)-11.04%
Revenue beat(12)3
Avg Revenue beat(12)-9.16%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)30.91%
EPS NQ rev (1m)-131.58%
EPS NQ rev (3m)-1000%
EPS NY rev (1m)-107.5%
EPS NY rev (3m)-876.47%
Revenue NQ rev (1m)-5.37%
Revenue NQ rev (3m)-6.29%
Revenue NY rev (1m)-6.81%
Revenue NY rev (3m)-27.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.95
P/S 1.54
P/FCF N/A
P/OCF N/A
P/B 482.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)0.31
Fwd EY11.17%
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS1.78
BVpS0.01
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -320.77%
ROE -42037.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.4
Health
Industry RankSector Rank
Debt/Equity 53.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.84
Altman-Z -12.46
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2855.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.97%
EPS Next Y63.82%
EPS Next 2Y45.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-67.73%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-23.65%
Revenue Next Year47.45%
Revenue Next 2Y83.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3934%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-937.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-924.59%
OCF growth 3YN/A
OCF growth 5YN/A